- Indication
- Diabetes
- RAG rating
- Amber initiation
- Document type
- Patient information
- Place
- Hertfordshire and West Essex ICB
- Output type
- Pharmacy / Prescribing
- Document
- Download
Dexcom ONE
Dexcom ONE Continuous Glucose Monitoring (CGM) system: Patient Information Letter
You have been given a Dexcom ONE CGM system which continuously measures glucose concentration and replaces the need for routine finger prick tests. The Diabetes Team ask that you take responsibility for using the CGM system correctly.
By receiving the CGM system, you are expected to:
- Attend appointments arranged by the Diabetes Team and GP or re-arrange them if you are unable to attend.
- Attend the recommended CGM training to understand what the device is showing and what action(s) to take.
- Attend or give due consideration to attending an appropriate diabetes education programme.
- Wear the sensor at least 70% of the time, reducing the use of standard blood glucose testing strips, as advised by the Diabetes Team.
- Share blood glucose testing and continuous glucose monitoring information with the Diabetes Team.
- Undertake appropriate actions relating to your diabetes management, as advised by the Diabetes Team.
- Agree to your data being shared for audit purposes.
- Agree to change to a lower cost blood glucose testing meter and strip where appropriate, as requested by the Diabetes Team.
- Contact the manufacturer (Dexcom Technical Support Line, Tel: 0800 031 5763) for further supplies if the sensor or transmitter are suspected to be defective or if the sensor falls off before it is due to be changed. A maximum of 37 sensors and 4 transmitters will be provided over any 12-month period.
Sensors and transmitters will continue to be provided if the above conditions are met and if:
- Clear evidence of an initial and ongoing improvement in your diabetes self-management has been demonstrated.
- The criteria for funding continue to be fulfilled.
- For patients who are pregnant, sensors and transmitters will be provided for a 12-month total treatment period (inclusive of post-delivery period) – unless any of the other criteria for funding is fulfilled.
- Version number
- 1.0
- Developed by
- HWE ICB PMOT
- Approved by
- HWE APC
- Date approved / updated
- December 2022
- Review date
- This HWE APC document is based upon the information available at the time of publication. This document will be reviewed upon request in light of new information becoming available.
- Superseded version
- n/a